Noticias y Actividades de Kodiak Sciences
Presencia
Kodiak Sciences es una de las ...
Kodiak Sciences es una empresa que cotiza bajo el símbolo de cotización KOD (US).
Ejecutivos
Ver el organigrama con sus 19 ejecutivos principales
Biografías más buscadas en Kodiak Sciences
- Victor Perlroth, Chairman and Chief Executive Officer
- Charles Bancroft, Director
- Taiyin Yang, Director
Recientes movimientos de ejecutivos en Kodiak Sciences
- Wayne To que ha sido Vice President and Senior Scientific Fellow, ha ascendido a Chief Technology Officer (noticia publicada el 18 de agosto de 2024).
- Dolly Chang, se ha incorporado a la empresa como Chief Scientific Officer (noticia publicada el 15 de agosto de 2024).
- Pablo Velazquez-Martin que ha sido Senior Vice President, Clinical Research and Translational Medicine, ha ascendido a Chief Medical Officer (noticia publicada el 15 de agosto de 2024).
Haga clic aquí para ver otros movimientos en Kodiak Sciences
Crear su alerta
para seguir los movimientos de los ejecutivos en Kodiak Sciences.
Biotecnología
Kodiak Sciences tiene 2.350 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Genus (Reino Unido).
Popular M&A news in Biotecnología
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 4 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Kodiak Sciences
- Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion | Kodiak Sciences Inc.
- Kodiak Sciences to Present at Upcoming Conferences | Kodiak Sciences Inc.
- Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights | Kodiak Sciences Inc.
- Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases | Kodiak Sciences Inc.
- Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress | Kodiak Sciences Inc.
- Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Society of Retin
- Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar | Kodiak Sciences Inc.
- Kodiak Sciences to Present at Upcoming Conferences | Kodiak Sciences Inc.
- Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference | Kodiak Sciences Inc.
- Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights | Kodiak Sciences Inc.
- View more press releases Close
Redes sociales sobre Kodiak Sciences
- Kodiak Sciences en Wikipedia, Google News y Yahoo Finance
- Kodiak Sciences en LinkedIn, Twitter y YouTube
